文献速递冠心病

直接PCI中冠脉内低剂量阿替普酶治疗STEMI伴高血栓负荷的随机试验

Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-10-28

STRIVE多中心随机双盲试验将210例接受直接PCI的大面积STEMI且高血栓负荷患者随机分为冠脉内阿替普酶10mg、20mg或安慰剂组,主要复合终点(30天MACE、心肌灌注分级0/1、远端栓塞、30分钟ST段回落不足50%)在联合阿替普酶组为53.3%,安慰剂组为52.9%(RR 1.00,95%CI 0.76-1.31,P>0.99),低剂量阿替普酶未优于安慰剂。

要点

  • 冠脉内低剂量阿替普酶未减少直接PCI患者的主要复合终点事件。
  • 各剂量组与安慰剂组结果一致,大出血罕见。
  • 阿替普酶组室颤有增多趋势(10.2% vs 1.4%,P=0.06)。

核心结论

  • 在STEMI高血栓负荷直接PCI患者中,冠脉内低剂量阿替普酶未优于安慰剂降低主要复合终点。
  • 数据不支持该疗法的常规应用。

研究设计与样本

  • 多中心、随机、双盲试验,纳入接受直接PCI的大面积STEMI且高血栓负荷患者。
  • 210例随机,207例接受研究药物:阿替普酶10mg组68例、20mg组69例、安慰剂组70例。
  • 平均年龄62.6岁,女性占25%,症状发作至随机中位时间2.9小时。

主要发现

  • 主要复合终点在联合阿替普酶组发生73例(53.3%),安慰剂组37例(52.9%)(RR 1.00,95%CI 0.76-1.31,P>0.99)。
  • 主要终点各组分及每个剂量组与安慰剂比较结果一致。
  • 大出血或临床显著出血试验中仅1例(阿替普酶20mg组)。
  • 给药期间室颤有增多趋势:阿替普酶组10.2% vs 安慰剂组1.4%(RR 6.86,95%CI 0.91-51.4,P=0.06)。

临床怎么用

  • 不推荐对接受直接PCI的STEMI高血栓负荷患者常规冠脉内给予低剂量阿替普酶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), approximately one-half of patients experience distal embolization of thrombus causing microvascular obstruction and reduced myocardial tissue perfusion. Targeted, intracoronary delivery of low-dose recombinant tissue plasminogen activator (alteplase) might be an effective strategy for improving microvascular obstruction without increasing the risk of systemic bleeding. OBJECTIVES: This study aims to determine whether adjunctive intracoronary delivery of low-dose alteplase reduces microvascular obstruction or major adverse cardiac events (MACE) in patients undergoing primary PCI for STEMI and high thrombus burden. METHODS: We performed a multicenter, randomized, double-blind trial involving patients undergoing primary PCI for large territory STEMI and high thrombus burden. Patients were randomized to receive either alteplase 10 mg, alteplase 20 mg, or placebo (saline) administered directly into the infarct-related artery using a delivery catheter after antegrade reperfusion was established. The primary outcome was the composite of MACE, myocardial blush grade 0/1, distal embolization, or failure to achieve ≥50% ST-segment resolution at 30 minutes post-PCI. MACE was the composite of cardiovascular death, myocardial re-infarction, cardiogenic shock, or new-onset heart failure at 30 days. RESULTS: Of 210 patients who were randomized, 207 received study drug (n = 68 alteplase 10 mg, n = 69 alteplase 20 mg, and n = 70 placebo). The mean age was 62.6 years and 25% were female. The median time from symptom onset to randomization was 2.9 hours. The primary outcome occurred in 73 patients (53.3%) in the combined alteplase groups vs 37 (52.9%) in the placebo group (relative risk: 1.00; 95% CI: 0.76-1.31; P > 0.99). Results were consistent across all components of the primary outcome and for each dose group vs placebo. Major or clinically significant bleeding occurred in 1 patient in the trial (in the alteplase 20 mg group). During study drug administration, there was a trend to more episodes of ventricular fibrillation in the alteplase groups compared with the placebo group (10.2% vs 1.4%, relative risk: 6.86; 95% CI: 0.91-51.4; P = 0.06). CONCLUSIONS: Among patients undergoing primary PCI for STEMI and large thrombus burden, intracoronary administration of alteplase was not superior to placebo in reducing the composite primary outcome of MACE at 30 days, myocardial blush grade 0/1, distal embolization, or failure to achieve ≥50% ST-segment resolution. These data do not support the routine administration of this therapy in patients with STEMI undergoing primary PCI (STRIVE [Adjunctive, Low-dose tPA in Primary PCI for STEMI]; clinicaltrials.gov NCT03335839).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mehta, Pinilla-Echeverri, Tiong, et al. Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for ST-Segment Elevation Myocardial Infarction and Large Thrombus Burden: A Randomized Trial. J Am Coll Cardiol. 2025. PMID: 41194755. doi:10.1016/j.jacc.2025.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。